company background image
ZLAB logo

Zai Lab NasdaqGM:ZLAB Stock Report

Last Price

US$32.53

Market Cap

US$3.3b

7D

7.1%

1Y

115.1%

Updated

22 Apr, 2025

Data

Company Financials +

Zai Lab Limited

NasdaqGM:ZLAB Stock Report

Market Cap: US$3.3b

ZLAB Stock Overview

A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. More details

ZLAB fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 69.7% below our estimate of its fair value

Earnings are forecast to grow 59.07% per year

Risk Analysis

Volatile share price over the past 3 months compared to the US market


Zai Lab Limited Competitors

ACADIA Pharmaceuticals

NasdaqGS:ACAD

US$2.4b

Ultragenyx Pharmaceutical

NasdaqGS:RARE

US$3.3b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.7b

Veracyte

NasdaqGM:VCYT

US$2.4b

Price History & Performance

Summary of share price highs, lows and changes for Zai Lab
Historical stock prices
Current Share PriceUS$32.53
52 Week HighUS$39.77
52 Week LowUS$15.00
Beta1.09
1 Month Change-7.30%
3 Month Change22.16%
1 Year Change115.15%
3 Year Change-21.08%
5 Year Change-48.86%
Change since IPO80.72%

Recent News & Updates

Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks

Mar 20

Zai Lab Limited's (NASDAQ:ZLAB) 31% Share Price Surge Not Quite Adding Up

Mar 06
Zai Lab Limited's (NASDAQ:ZLAB) 31% Share Price Surge Not Quite Adding Up

Recent updates

Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks

Mar 20

Zai Lab Limited's (NASDAQ:ZLAB) 31% Share Price Surge Not Quite Adding Up

Mar 06
Zai Lab Limited's (NASDAQ:ZLAB) 31% Share Price Surge Not Quite Adding Up

Investors Don't See Light At End Of Zai Lab Limited's (NASDAQ:ZLAB) Tunnel

Jan 20
Investors Don't See Light At End Of Zai Lab Limited's (NASDAQ:ZLAB) Tunnel

Zai Lab: Rapidly Improving Outlook Bodes Well For The Future

Dec 26

The Zai Lab Limited (NASDAQ:ZLAB) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 15
The Zai Lab Limited (NASDAQ:ZLAB) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Zai Lab Limited (NASDAQ:ZLAB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Sep 28
Zai Lab Limited (NASDAQ:ZLAB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?

Sep 23
Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?

Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why

Jun 12
Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why

Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified

May 14
Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified

A Risky Bet: Zai Lab's Uncertain Future

Apr 16

Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

Mar 29
Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop

We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Mar 24
We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely

Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S

Jan 18
Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S

Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation

Sep 22
Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation

Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 24
Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth

Jun 02
We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth

Shareholder Returns

ZLABUS BiotechsUS Market
7D7.1%1.7%-1.7%
1Y115.1%-6.0%3.6%

Return vs Industry: ZLAB exceeded the US Biotechs industry which returned -7.1% over the past year.

Return vs Market: ZLAB exceeded the US Market which returned 2.5% over the past year.

Price Volatility

Is ZLAB's price volatile compared to industry and market?
ZLAB volatility
ZLAB Average Weekly Movement11.6%
Biotechs Industry Average Movement11.4%
Market Average Movement7.7%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market4.1%

Stable Share Price: ZLAB's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ZLAB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

Community vs My Fair Value

Select a narrative for quick price alerts from the community, or create your own.

About the Company

FoundedEmployeesCEOWebsite
20131,869Samantha Duwww.zailaboratory.com

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company’s oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride.

Zai Lab Limited Fundamentals Summary

How do Zai Lab's earnings and revenue compare to its market cap?
ZLAB fundamental statistics
Market capUS$3.26b
Earnings (TTM)-US$257.10m
Revenue (TTM)US$398.99m

8.9x

P/S Ratio

-13.9x

P/E Ratio

Is ZLAB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ZLAB income statement (TTM)
RevenueUS$398.99m
Cost of RevenueUS$382.36m
Gross ProfitUS$16.62m
Other ExpensesUS$273.73m
Earnings-US$257.10m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 08, 2025

Earnings per share (EPS)-2.35
Gross Margin4.17%
Net Profit Margin-64.44%
Debt/Equity Ratio15.7%

How did ZLAB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/22 14:54
End of Day Share Price 2025/04/22 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zai Lab Limited is covered by 31 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael MengBOCI Research Ltd.
Wai Chak YuenBOCI Research Ltd.
Linda LuBOCI Research Ltd.